Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

To prevent relapse or reinfection, melioidosis requires a specific and prolonged treatment. Melioidosis is endemic at least 45 countries, but greatly under-reported, with a microbiological culture required to confirm diagnosis. This can take 2-7 days. In Thailand, up to 40 percent of hospital admitted melioidosis patients die. Premjit works with MORU researchers who have produced a rapid diagnostic test that aims to improve both diagnosis and public awareness of melioidosis.

My name is Premjit Amornchai. I come from Ubon Ratchathani, in the northeast of Thailand. I am the BSL 3 Lab Manager, Area Safety Officer and a Microbiologist at MORU.

Q: What kind of materials do you handle in your BSL 3 lab?

Premjit Amornchai: The material I handle is Burkholderia pseudomallei. This organism has been classified as a bioweapon organism by the CDC, USA. This is a dangerous bacteria. It can normally be found in rice paddy fields, in the soil and in the water. Thailand, especially the northeast of Thailand, is an endemic area for melioidosis, the disease caused by this bacteria. This disease is not unknown, just under reported. We need to promote and give knowledge to physicians and microbiologists so they know about this organism. This disease is endemic not only in Thailand and Australia, but also around the world; China also has cases of melioidosis, Malasia, Lao also because they are neighbours of Thailand, as well as Cambodia, Brazil, Bangladesh.

The symptoms of melioidosis are similar to those of other diseases like TB, malaria, leptospirosis or scrub typhus, so it is difficult to diagnose. Melioidosis also needs a specific treatment which is different from other bacterial infections. Melioidosis needs prolonged treatment: the treatment is completed in around 20 weeks. If you do not complete the treatment, you can relapse or be reinfected again. In Thailand, especially in the northeast, the mortality rate is 40%. For other countries, I think it is less than that, but it is still high and we need them to be aware of this disease.

Q: What are the challenges and difficulties in your work?

PA: The challenge of my work is to improve our rapid test to help diagnose melioidosis and to reduce the diagnosis time. In the past, we used the standard immunofluorescence antibody assay to detect the antigen of Burkholderia pseudomallei from clinical samples. That took around 2 hours, but right now, we take only 15 minutes to get results.

Q: What are the benefits for you working at MORU? What do you like about it?
PA: Oh, I like everything, especially I learned a lot how to do research here, how to work with the team. In MORU, we have many research groups such as scrub typhus group, rickettsia group and also the malaria group, molecular, cell bio, immunology. We have many groups that we can share opinions with and share the work together. If we want to collaborate with others, they are always happy to join us.

Premjit Amornchai

Bio-Safety Level 3 Laboratory

Microbiologist Premjit Amornchai heads MORU's Bio-Safety Level (BSL) 3 Laboratory in Bangkok, Thailand. Safety is very important for Premjit. The BSL3 Lab handles several dangerous materials, most notably, Burkholderia pseudomallei, a highly pathogenic bacterium commonly found in soil and water in Southeast Asia and northern Australia. The pathogen causes the difficult to diagnose, deadly bacterial infection melioidosis.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.